![]() | |
Clinical data | |
---|---|
Other names | PF-734200 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H24F2N6O |
Molar mass | 366.417 g·mol−1 |
3D model (JSmol) | |
| |
|
Gosogliptin (INN; trade name Saterex) is a drug for the treatment of type II diabetes. It is in the class of dipeptidyl peptidase-4 (DPP-4) inhibitors (also called gliptins). It was discovered [1] and developed through Phase 1 [2] [3] [4] and Phase 2 [5] [6] [7] by Pfizer. The crystal structure of DPP-4 in complex with gosogliptin is available. [8] Its metabolism, excretion and pharmacokinetics in rat, dog and human have been described. [9] A cost efficient route has been published. [10] Other studies [11] including Phase 3 studies were conducted in Russia. [12] [13] It is approved for use in Russia. [14]